This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Take the Zacks Approach to Beat the Markets: NVIDIA, Seagate, Amkor in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe
by Zacks Equity Research
Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe are included in this Analyst Blog.
Why Amgen (AMGN) Outpaced the Stock Market Today
by Zacks Equity Research
Amgen (AMGN) closed at $319.31 in the latest trading session, marking a +0.36% move from the prior day.
Top Stock Reports for Chevron, Amgen & Philip Morris
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and Philip Morris International Inc. (PM), as well as two micro-cap stocks Hurco Companies, Inc. (HURC) and Perma-Pipe International Holdings, Inc. (PPIH).
Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $309.89, moving +1.27% from the previous trading session.
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
by Zacks Equity Research
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
by Zacks Equity Research
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
by Zacks Equity Research
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Why Amgen (AMGN) Dipped More Than Broader Market Today
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $305.02, moving -0.22% from the previous trading session.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
by Zacks Equity Research
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
by Zacks Equity Research
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.